BACKGROUND: Liver ischemia and reperfusion (IR) injury is a phenomenon that leads to graft dysfunction after liver transplantation. Understanding the molecular mechanisms behind this process is crucial to developing strategies to prevent short- and long-term graft dysfunction. The purpose of this study was to explore the role of the transcription factor interferon regulatory factor-1 (IRF-1) in a model of orthotopic rat liver transplantation. METHODS: Orthotopic syngeneic LEW rat liver transplantation (OLT) was performed after 18 or 3 hours preservation in cold University of Wisconsin solution. Adenovirus-expressing IRF-1 (AdIRF-1) or control gene vector (Adnull) was delivered to the liver by donor intravenous pretreatment 4 days before graft harvesting. Uninfected grafts also served as controls. Recipients were humanely killed 1-24 hours post-transplantation. RESULTS: Rats that underwent OLT with long-term preserved grafts (18 hours) displayed increased hepatic nuclear expression of IRF-1 protein at 1 and 3 hours. Rats pretreated with AdIRF-1 before transplantation had elevated alanine aminotransferase levels and increased expression of interferon (IFN)-beta, IFN-gamma, interleukin-12, and inducible nitric oxide synthase in the short-term period (3 hours) when compared with donor livers pretreated with Adnull. AdIRF-1 pretreated donor livers also exhibited increased susceptibility to early apoptosis in the transplanted grafts as shown by increased terminal deoxynucleotidyl transferase mediated dUTP nick end labeling (TUNEL) staining and expression of cleaved caspase-3. Additionally, AdIRF-1 pretreated donor livers had increased activation of the MAP kinase Jun N-terminal kinase as compared with Adnull pretreated donor livers. CONCLUSION: IRF-1 is an important regulator of IR injury after OLT in rats. Targeting of IRF-1 may be a potential strategy to ameliorate ischemic liver injury after transplantation to minimize organ dysfunction.
BACKGROUND:Liver ischemia and reperfusion (IR) injury is a phenomenon that leads to graft dysfunction after liver transplantation. Understanding the molecular mechanisms behind this process is crucial to developing strategies to prevent short- and long-term graft dysfunction. The purpose of this study was to explore the role of the transcription factor interferon regulatory factor-1 (IRF-1) in a model of orthotopic rat liver transplantation. METHODS: Orthotopic syngeneic LEW rat liver transplantation (OLT) was performed after 18 or 3 hours preservation in cold University of Wisconsin solution. Adenovirus-expressing IRF-1 (AdIRF-1) or control gene vector (Adnull) was delivered to the liver by donor intravenous pretreatment 4 days before graft harvesting. Uninfected grafts also served as controls. Recipients were humanely killed 1-24 hours post-transplantation. RESULTS:Rats that underwent OLT with long-term preserved grafts (18 hours) displayed increased hepatic nuclear expression of IRF-1 protein at 1 and 3 hours. Rats pretreated with AdIRF-1 before transplantation had elevated alanine aminotransferase levels and increased expression of interferon (IFN)-beta, IFN-gamma, interleukin-12, and inducible nitric oxide synthase in the short-term period (3 hours) when compared with donor livers pretreated with Adnull. AdIRF-1 pretreated donor livers also exhibited increased susceptibility to early apoptosis in the transplanted grafts as shown by increased terminal deoxynucleotidyl transferase mediated dUTP nick end labeling (TUNEL) staining and expression of cleaved caspase-3. Additionally, AdIRF-1 pretreated donor livers had increased activation of the MAP kinase Jun N-terminal kinase as compared with Adnull pretreated donor livers. CONCLUSION:IRF-1 is an important regulator of IR injury after OLT in rats. Targeting of IRF-1 may be a potential strategy to ameliorate ischemic liver injury after transplantation to minimize organ dysfunction.
Authors: Allan Tsung; Michael T Stang; Atsushi Ikeda; Nathan D Critchlow; Kunihiko Izuishi; Atsunori Nakao; Meagan H Chan; Geetha Jeyabalan; John H Yim; David A Geller Journal: Am J Physiol Gastrointest Liver Physiol Date: 2006-01-12 Impact factor: 4.052
Authors: S Natori; M Selzner; K L Valentino; L C Fritz; A Srinivasan; P A Clavien; G J Gores Journal: Transplantation Date: 1999-07-15 Impact factor: 4.939
Authors: Seigo Nishida; Noboru Nakamura; Jun Kadono; Teruo Komokata; Ryuzo Sakata; Juan R Madariaga; Andreas G Tzakis Journal: J Hepatobiliary Pancreat Surg Date: 2006-11-30
Authors: Eduardo E Montalvo-Jave; Tomas Escalante-Tattersfield; Jose A Ortega-Salgado; Enrique Piña; David A Geller Journal: J Surg Res Date: 2007-07-27 Impact factor: 2.192
Authors: Thomas H J Mueller; Klaus Kienle; Alexander Beham; Edward K Geissler; Karl W Jauch; Markus Rentsch Journal: Transplantation Date: 2004-11-15 Impact factor: 4.939
Authors: Allan Tsung; John R Klune; Xianghong Zhang; Geetha Jeyabalan; Zongxian Cao; Ximei Peng; Donna B Stolz; David A Geller; Matthew R Rosengart; Timothy R Billiar Journal: J Exp Med Date: 2007-11-05 Impact factor: 14.307
Authors: John R Klune; Rajeev Dhupar; Shoko Kimura; Shinya Ueki; Jon Cardinal; Atsunori Nakao; Gary Nace; John Evankovich; Noriko Murase; Allan Tsung; David A Geller Journal: Am J Physiol Gastrointest Liver Physiol Date: 2012-06-28 Impact factor: 4.052
Authors: Shinichiro Yokota; Osamu Yoshida; Lei Dou; Anthony V Spadaro; Kumiko Isse; Mark A Ross; Donna B Stolz; Shoko Kimura; Qiang Du; Anthony J Demetris; Angus W Thomson; David A Geller Journal: J Immunol Date: 2015-05-11 Impact factor: 5.422
Authors: John R Klune; Christian Bartels; Jing Luo; Shinichiro Yokota; Qiang Du; David A Geller Journal: Am J Physiol Gastrointest Liver Physiol Date: 2018-10-11 Impact factor: 4.052
Authors: P Fontes; R Lopez; A van der Plaats; Y Vodovotz; M Minervini; V Scott; K Soltys; S Shiva; S Paranjpe; D Sadowsky; D Barclay; R Zamora; D Stolz; A Demetris; G Michalopoulos; J W Marsh Journal: Am J Transplant Date: 2015-02 Impact factor: 8.086
Authors: Mu-Qing Yang; Qiang Du; Patrick R Varley; Julie Goswami; Zhihai Liang; Ronghua Wang; Hui Li; Donna B Stolz; David A Geller Journal: Br J Cancer Date: 2017-11-07 Impact factor: 7.640